Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This article discusses the considerations and challenges surrounding a proposed large-scale trial on testosterone-replacement therapy in older men and reports no new results.

This study found that 5‐α‐reductase inhibitors reduce the risk of being diagnosed with prostate cancer in men who undergo regular screening, but increase the risk of sexual and erectile dysfunction.

Systematic end-of-trial biopsies are the most reliable way to assess outcomes.

This review concludes that while many epidemiological studies suggest high alcohol intake is associated with an increased risk of prostate cancer, the evidence may be affected by confounding factors such as diet and lifestyle.

This study reports that 5-alpha-reductase inhibitors do not prevent prostate cancer and merely reduce the likelihood of undergoing diagnostic biopsies, potentially misleading patients and physicians.

The document concludes that accurately identifying leukemia types is crucial, and the risks of cancer from finasteride need careful evaluation against its benefits.

This article discusses the role of 5-alpha-reductase inhibitors in prostate cancer prevention and highlights a medical quandary, but it reports no new clinical findings.

This study found that finasteride reduced prostate cancer incidence by 30%, with no significant difference in Gleason scores compared to placebo after re-evaluation of pathology and extended follow-up.

This article examines the PCPT study on whether daily finasteride can reduce prostate cancer incidence, describing its methodology and findings but reporting no new clinical results.

This report from a consensus meeting concluded that while 5-alpha reductase inhibitors are beneficial for BPH treatment and prostate cancer risk reduction, their role in clinical practice should be more widely integrated into prostate management guidelines.

This study suggests that simple absolute threshold monitoring rules for compliance using the biomarker DHT perform similarly to more complex methods in the Prostate Cancer Prevention Trial.

5α-reductase inhibitors can reduce prostate cancer risk but may increase high-grade tumors, needing more research.

This study found that non-adherence to medication in the Prostate Cancer Prevention Trial was associated with increased all-cause mortality unrelated to prostate cancer.

This study found that both finasteride and dutasteride reduced the risk of prostate cancer detection, but finasteride was associated with an increased diagnosis of higher-grade disease, unlike dutasteride.

This article concludes that finasteride is a safe treatment for androgenetic alopecia and does not increase the risk of high-grade prostate cancer, despite past concerns from the Prostate Cancer Prevention Trial.

Finasteride is beneficial for BPH but requires careful monitoring due to cancer risks.

This review discusses preclinical and clinical chemoprevention research for several cancers, noting challenges in effectiveness and toxicity, and emphasizes the need for further trials.

Dutasteride reduces prostate cancer risk by 23% in high-risk men.

Finasteride lowers prostate cancer risk but may increase high-grade tumors and sexual side effects.

Finasteride may reduce prostate cancer risk.

This article from BJU International discusses the slow progress in prostate cancer research and reports no new findings.

Finasteride is safe for long-term use in prostate cancer treatment.

This review summarizes existing studies on 5-alpha reductase inhibitors, noting their effectiveness in reducing prostate volume and cancer risk but highlighting an increased risk of higher grade prostate cancer.

This review discusses persistent adverse effects of 5α‐reductase inhibitors, like diminished libido and erectile dysfunction, in some patients and highlights the need for patient discussions before therapy, especially for androgenetic alopecia.

Finasteride for hair loss may increase the risk of certain cancers and has side effects; better regulation and education on its use are needed.

This study observed that finasteride use among men with benign prostatic hyperplasia was associated with a decreased incidence of low-grade prostate cancer but not high-grade tumors.

In this study, applying case-only trees and random forests to a prostate cancer prevention trial revealed genotypes that may influence the efficacy of finasteride for prostate cancer prevention.

This article discusses the potential of finasteride as a chemopreventive agent for prostate cancer and highlights unresolved issues, but it reports no new research findings.

The authors concluded that dutasteride is effective and generally safe for managing benign prostatic hyperplasia and may reduce prostate cancer risk.